Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | MMP8 | P22894 | 3/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PYGL | P06737 | 3/20 | 0.43 |
| ▸ | F13A1 | P00488 | 2/20 | 0.42 |
| ▸ | TGM2 | P21980 | 2/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205257 | 1.00 | MMP9 (0.50) | MMP9MMP8MMP14CAPN1KMT2A | |
| SCHEMBL7205316 | 0.92 | MMP9 (0.55) | MMP9MMP8MMP14CAPN1KMT2A | |
| SCHEMBL7205323 | 0.92 | MMP9 (0.55) | MMP9MMP8MMP14CAPN1KMT2A | |
| Hydrochloric Acid SCHEMBL7208321 | 0.90 | MMP9 (0.48) | MMP9MMP8MMP14CAPN1KMT2A | |
| Hydrochloric Acid SCHEMBL7208324 | 0.90 | MMP9 (0.48) | MMP9MMP8MMP14CAPN1KMT2A | |
| SCHEMBL7202948 | 0.89 | MMP9 (0.50) | MMP9MMP8MMP14CAPN1KMT2A | |
| SCHEMBL7202940 | 0.89 | MMP9 (0.50) | MMP9MMP8MMP14CAPN1KMT2A | |
| SCHEMBL7207193 | 0.88 | F13A1 (0.56) | MMP9MMP8MMP14CAPN1F13A1 | |
| SCHEMBL14513403 | 0.88 | MMP9 (0.63) | MMP9MMP8MMP14CAPN1KMT2A | |
| SCHEMBL7203445 | 0.88 | MMP9 (0.48) | MMP9MMP8MMP14CAPN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | MED INSTITUTE, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | MED INSTITUTE, INC. | 2007-12-20 | — | — | US | disclosed |
| EP-0921122-B1 | EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-05-21 | — | — | EP | disclosed |
| US-6110967-A | USEFUL AS AGENTS FOR PREVENTING AND TREATING METABOLIC OSTEOPATHY SUCH AS OSTEOPOROSIS, HYPERCALCEMIA AND BONE METASTASIS OF CANCER BECAUSE THEY SPECIFICALLY INHIBITS CATHEPSIN L AND ITS FAMILY ENZYMES TO INHIBIT BONE RESORPTION | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0921122-A1 | NOVEL EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1999-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293937-A1 | Endoluminal medical device for local delivery of cathepsin inhibitors, method of making and treating | CTSS, CTSD, CTSV | MMP9 91/4885MMP8 95/4885MMP14 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.